Kornimate/medical-research-clean huggingface dataset:
colorectal cancer screening using stool dna-based sdc2 and sfrp2 methylation test in china

Conditions: Colorectal Neoplasm; Colorectal Cancer; Adenomatous Polyps; Adenoma; Advanced Adenoma; Serrated Polyp

Summary: the primary objective is to determine sensitivity, specificity, positive predictive value and negative predictive value of a bi-target stool dna testing (the methylation status of sdc2 and sfrp2) for colorectal cancer and advanced precancerous neoplasm(including advanced adenoma and advanced serrated lesions) screening, using colonoscopy as the reference method. lesions will be confirmed as malignant or precancerous by histopathologic examination. the secondary objective is to compare the performance of the bi-target stool dna testing to a commercially available fecal immunochemical test (fit) assay, both with respect to cancer and advanced precancerous neoplasm. lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

this study is a multi-center diagnostic test led by the national clinical research center for digestive disease (shanghai) (department of gastroenterology, changhai hospital, navy/second military medical university), which is conducted at about 30 digestive endoscopy centers nationwide in china, with the expectation of including approximately 4,800 patients. subjects willing to conduct colonoscopy examination will be asked to collect stool sample prior to bowl preparation for stool dna test and commercially available fit assay. the basic characteristics of subjects, bowel preparation method and quality, and related information of colonoscopy are recorded in detail. colonoscopy and histopathologic examination are used as reference.

Eligibility criteria:
inclusion criteria: 1. age between 40 to 85 years old, the gender is not limited 2. willing to provide written consent 3. able to provide stool sample exclusion criteria: 1. unwilling to provide stool samples 2. subject with contraindications for bowel preparation or colonoscopy 3. subject with known colorectal polyps but not removed 4. subject with inflammatory bowel disease 5. history of colonoscopy within 1 year 6. history of colorectal cancer 7. history of hereditary colorectal cancer syndrome (including polyposis) 8. active lower gastrointestinal bleeding 9. pregnancy 10. subject taking anticoagulants such as aspirin and warfarin, or who have coagulopathy 11. subject clinically highly suspected with gastrointestinal cancer 12. other conditions deemed not suited for the study by investigators elimination criteria: 1. ask to withdraw from the study 2. unable to get a stool sample 3. invalid stool samples to test 4. poor or inadequate bowel preparation 5. failed to complete the colonoscopy
oct in open fracture and infected fracture

Conditions: Trauma Injury; Trauma; Open Fracture; Fracture Infection

Summary: this is a pilot prospective, observational study of patients with open or infected fracture evaluating the feasibility and acceptability of oct, a light-based imaging modality that requires no drug or contrast agent.


Eligibility criteria:
inclusion criteria: * age 18 years or older * open fracture * fracture related infection exclusion criteria: * metatarsal fractures
a study to evaluate the safety and efficacy of lotemax ophthalmic suspension 0.5%

Conditions: Conjunctivitis, Seasonal Allergic; Conjunctivitis, Giant Papillary; Inflammation

Summary: the objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

the objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice after marketing authorization of lotemax ophthalmic suspension 0.5%

Eligibility criteria:
inclusion criteria: * subjects who have been treated with the study drug at least once and completed safety follow-up. * subjects who have been treated with the study drug at least once and completed the clinical efficacy assessment. exclusion criteria: * subjects not treated with study drug at least once.

Keywords: post-operative inflammation conjunctivitis safety seasonal allergic conjunctivitis giant papillary conjunctivitis
identifying risk factors (rf) for early haemodialysis arteriovenous fistula failure (eavff)

Conditions: Arteriovenous Fistula; Hemodialysis; End Stage Chronic Renal Failure

Summary: arteriovenous fisutla (avf) is the vascular access of choice for hemodialysis but has a high early failure (eavff) rate. eavff can be defined as thrombosis/stenosis and doppler ultrasound (dus)-based failure-to-mature parameters such as postoperative blood flow (postqa) \< 500 ml/min, avf-vein diameter (postvd) \< 5 mm, and avf-vein depth (postvdepth) ≥ 6 mm. we explored whether common risk factors for eavff could predict these eavff parameters and venous distensibility: the latter is largely overlooked as a potential eavff parameter.


Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years) * patients who had undergone distal (radioradial and radiocephalic) or proximal arteriovenous fistula (avf) access creation surgery between 2016 and 2021 at the chr metz-thionville. * patients who underwent preoperative and postoperative doppler ultrasound (dus) ≤ 4 months after surgery. * patients with central venous catheter (cvc) at surgery exclusion criteria: * patients using the fistula for intermittent plasmapheresis * patients with a radiobasilic avf or arteriovenous graft
reandron in diabetic men witn low testosterone level

Conditions: Type 2 Diabetes; Hypogonadism

Summary: in men with type 2 diabetes, low testosterone levels have been associated with insulin resistance, truncal obesity and symptoms such as fatigue and erectile dysfunction. low testosterone may impair cardiac function and increase cardiovascular risk and cause osteoporosis. the goal of this project is to assess prospectively whether, in men with type 2 diabetes mellitus and low testosterone levels, testosterone replacement improves insulin resistance, body composition, bone density, cardiac function symptoms associated with low testosterone level. the investigators will recruit 140 ambulatory men with type 2 diabetes and a low serum testosterone level (\<10 nmol/l) from austin health endocrine clinics, general practise surgeries, and from the general public by direct consumer advertising via newspaper and other local media. men will be randomised to either intramuscular testosterone undecanoate (reandron 1000, bayer schering pharma) or placebo. men with contraindications to testosterone replacement or to intramuscular injections will be excluded from the study. all men will receive intramuscular testosterone or placebo injections at 0, 6, 18 and 30 weeks (a total of four injections). all 140 study subjects will have a clinical and laboratory assessment at baseline, 18 weeks and at study end (40 weeks). all 140 subjects will also have imaging studies at baseline and at study end (40 weeks). the study protocol is outlined in more detail below: clinical and laboratory assessment (baseline and repeated 18 weeks, 40 weeks) a full medical history and physical examination will be performed. symptoms will be assessed by the following standardised questionnaires: 1) androgen deficiency in the aging male (adam); 2) aging male symptom scale (ams); 3) international index of erectile dysfunction (iied); 4) international prostate symptom score (ipss); 5) sf-36 (all five questionnaires are attached to module 1). laboratory studies will consist of blood tests to measure total testosterone, fasting glucose, c-peptide, hba1c and other routine parameters. imaging studies (baseline and repeated at 40 weeks) 1. body composition and bone mineral density by dexa 2. body composition by magnetic resonance imaging 3. bony micro-architecture by high resolution quantitative computed tomography \[hr-pqct\]), 4. cardiac dimensions and function by transthoracic doppler echocardiography


Eligibility criteria:
inclusion criteria: * type 2 diabetes * testosterone less than 10 nmol/l exclusion criteria: * contraindication to * testosterone or * im injection
identification of circulating tumor cells in the peripheral blood of lung cancer patients

Conditions: Lung Cancer

Summary: the primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

the purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as cd44 and epithelial specific antigen.

Eligibility criteria:
inclusion criteria:inclusion criteria:inclusion criteria (cases): 1. advanced stage (iiib with malignant effusion or iv) histologically or cytologically confirmed nsclc 2. patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection 3. ability to sign informed consent 4. at least 18 years of age inclusion criteria (controls): 1. no known prior or active malignancy 2. ability to sign informed consent 3. at least 18 years of age exclusion criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years exclusion criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years 2. pregnant women
up-positioning of the testes as supportive therapy in patients with acute orchitis

Conditions: Orchitis; Testicular Diseases

Summary: this is a single-blinded rct evaluating the value of up-positioning of the testes as supportive therapy in patients receiving antimicrobial treatment due to acute bacterial orchitis.


Eligibility criteria:
inclusion criteria: * acute orchitis confirmed clinically and in scrotal ultrasound * age \>=18 yrs exclusion criteria: * previous treatment of orchitis, * need for exploration of the scrotum, * need for hospitalization, * physical and mental status not allowing for up-positioning of the testes during treatment

Keywords: orchitis testicular diseases
positron emission tomography/computed tomography (pet/ct) in relapsed ovarian cancer (mk-0000-143)

Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer

Summary: this study will characterize fdg-pet (18f-fluorodeoxyglucose-positron emission tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.


Eligibility criteria:
inclusion criteria: * patient has ovarian, primary peritoneal, or fallopian tube cancer * patient has first or subsequent relapse * patient has had at least on prior platinum-based treatment for ovarian cancer * patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum * patient is not pregnant exclusion criteria: * patient has had abdominal surgery within the last 6 weeks * patient has life expectancy \< 6 months * patient has had radiotherapy to the abdomen or pelvis within the last 6 months * patient has poorly controlled diabetes

Keywords: relapsed ovarian cancer
microwave ablation in combination with camrelizumab versus camrelizumab in metastatic non-small-cell lung cancer

Conditions: NSCLC Stage IV

Summary: patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.patients in the combination group were treated with mwa in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days. the primary end point is overall survival. the second end points include progression free survival, objective response rate and safety.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 75 years old 2. cytologically or pathologically verified non-small cell lung cancer (nsclc) 3. patients with distant metastases or postoperative recurrence 4. egfr or alk sensitive mutations are negative (all patients, including non-adenocarcinoma patients) 5. at least one line of platinum-based doublet chemotherapy was administrated 6. eastern cancer cooperative group（ecog）performance status（ps）of 0 to 1 7. at least two measurable tumors (in other words a measurable tumor lesion exclusive primary tumors) 8. asymptomatic brain metastases or symptomatic brain metastases under control 9. if treated with irradiation，at least one month interval between radiation and randomization 10）cardiopulmonary function, laboratory test indicators without ablation or chemotherapy contraindications 11) informed conssent can be obtained 12) sufficient tissue specimens for pd-l1 or tmb or blood samples were provided (1 week before treatment, 1 week after ablation, and once every two months for immune evaluation) for subsequent analysis exclusion criteria: 1. mixed lung cancer contains neuroendocrine tumor, small cell lung cancer or sarcoma 2. suffering from other malignant tumors within five years 3. egfr, alk sensitive mutations are positive or unknown 4. ecog ps≥2 5. uncontrolled pleural effusion or pericardial effusion 6. uncontrolled symptomatic brain metastases 7. previously anti-pd-1, anti-pd-l1, anti-ctla-4 or car-t immunotherapy 8. severe interstitial pneumonia with severe diffuse dysfunction 9. autoimmune diseases require long-term hormone therapy patients 10. patients required consistent application of prednisone 11. uncontrolled pulmonary infection or antibiotics stopped within 1 month 12. acute cardiovascular and cerebrovascular diseases such as acute cerebral infarction and acute coronary syndrome within 1 month 13. patients during pregnancy or lactation 14. life expectance of 3 months or less

Keywords: nsclc camrelizumab microwave ablation overall survival progression free survival objective response rate safety
pain post abdominal laparoscopy prevention with arcoxia

Conditions: Laparoscopic Surgery for Appendicitis; Laparoscopic Surgery for Cholecystitis; Laparoscopic Surgery for Ovarian Cysts

Summary: to test the analgesic efficacy of etoricoxib used before a surgical procedure compared to the already known effect when administered after such a procedure. patient will be receiving either etoricoxib or the respective placebo one hour before surgery, then two hours after those receiving the active will receive placebo and those that received placebo will be given etoricoxib. pain score measurements will be performed sequentially. rescue medication will be available all the time.


Eligibility criteria:
inclusion criteria: * voluntary acceptance to participate in the study and signed the informed consent form * age older than 18 years old and younger than 70 years * diagnosis of appendicitis, cholecystitis or ovarian cysts suitable of laparoscopic surgery exclusion criteria: * age less than 18 years or older than 70 years. * laparoscopic procedures for diagnostic purposes. * current use of anticoagulants. * known hypersensitivity to etoricoxib or its components. * history of a cabg or mi (less than 1 year) * history of unstable angina (over the past six months). * current inflammatory bowel disease. * uncontrolled hypertension or heart failure * renal dysfunction/impairment (creatinine clearance \< 30ml/min) * cirrhosis or severe hepatic dysfunction * any degree of dehydration (mild to severe)
efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

Conditions: Radiation Enteritis

Summary: at present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. therefore, the investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

screening: this phase will not last longer than one week, and the subject will be assessed for eligibility after signing the informed consent form. treatment: subjects were randomly assigned to three different treatment groups for 8 weeks. follow-up: the subjects' defecation status was recorded every day during treatment, telephone follow-up was conducted every two weeks, and laboratory indicators (including blood routine, stool routine, etc.) were tested every four weeks. the test was terminated one week after treatment and the improvement of subjects' stool blood was assessed.

Eligibility criteria:
inclusion criteria: * age 18-80 years old, gender is not limited; * patients with hematochezia symptoms of chronic radiation intestinal injury: due to the lack of diagnostic gold standard for radiation intestinal injury, a comprehensive analysis of clinical, endoscopic, imaging and histopathological findings was mainly performed to make the diagnosis of radiation intestinal injury on the basis of excluding infectious and other non-infectious intestinal injuries. exposure to radioactive sources is a necessary factor in the diagnosis of radiation intestinal injury, and tumor activity or recurrence should be excluded. * the proportion of dominant defecation bleeding in total defecation times in the week before treatment is not less than 20%; * ecog score: 0-2. exclusion criteria: * patients with hemodynamic instability; * patients with obvious liver and kidney function injury: bilirubin, aminotransferase (alt, ast) exceeded the upper limit of normal by 2 times; egfr\<60ml/min or dialysis patients; * patients allergic to thalidomide or glutamine; * patients whose primary disease was gastrointestinal malignancy; * patients currently suffering from serious or uncontrolled underlying diseases of the blood, digestive tract, metabolism, endocrine, lung, heart, nervous system, mental system, etc.; * female patients during pregnancy and breastfeeding (including patients with reproductive needs); * patients infected with hiv; * patients who cannot cooperate with regular follow-up and review of laboratory indicators; * any other circumstances which, in the opinion of the investigator, would render the subject unfit for study inclusion.
using digital data to predict chd

Conditions: Cardiovascular Diseases

Summary: this project seeks to identify and characterize features derived from digital data (e.g. social media, online search, mobile media) which are associated with coronary heart disease (chd) and related risk factors, and develop models that use digital data and conventional predictive models to predict chd risk and health care utilization.

cardiovascular disease is the leading cause of death in the us. while secondary prevention approaches have improved longevity of patients, risk factors and adverse health behaviors (e.g., physical inactivity, smoking) are highly prevalent, and in most contemporary series, less than 1% of adults meet all factors of ideal cv health. the logistics and practicalities of meeting the goal of ideal cv health have not been clearly elucidated. practice guidelines recommend using the framingham risk score (frs) or other risk prediction tools to classify patients' risk of cv disease. these models however are imprecise and there is increasing focus on identifying markers that provide better measures of risk. as digital platforms are increasingly used to document lifestyle and health behaviors, data from digital sources may provide a window into manifestations of novel risk factors and potentially a better characterization of existing risk factors. while it seems like a cliche to mention the profound impact of digital data on everyday lives, there is indeed great substance in the opportunities these new media provide for understanding behavioral, social, and environmental determinants of health. this project seeks to identify and characterize features derived from digital data (e.g. social media, online search, mobile media) which are associated with coronary heart disease (chd) and related risk factors, and develop models that use digital data and conventional predictive models to predict chd risk and health care utilization.

Eligibility criteria:
inclusion criteria: * 30 - 74 years of age * willing to sign informed consent * primarily english speaking (for language analysis) * has an account on any of the following digital data platforms (facebook, instagram, twitter reddit, google (gmail), or smartphone or wearable device such as apple health, fitbit, samsung health, mapmyfitness or garmin) and willing to share data * if has social media account, instagram or facebook, willing to share historical and prospective data (60 days) if has google (gmail) account, willing to download and share google takeout zip file * if has smartphone or wearable device, willing to share step data * willing to share access to medical health records * willing to share healthcare insurance information exclusion criteria: * patient does not meet age inclusion criteria above * does not use and post on digital data sources we are studying or unwilling to donate data * patient is in severe distress, e.g. respiratory, physical, or emotional distress * patient is intoxicated, unconscious, or unable to appropriately respond to questions

Keywords: digital data digital health